Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Azopt 1% Ophthalmic Suspension Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Prairie Eye Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

NCT00121147
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome
Interventions
Travatan, Azopt, Alphagan P
Drug
Lead sponsor
Hermann Eye Center
Other
Eligibility
35 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
21
States / cities
Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2006 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

NCT03896633
View directory record Official record
Conditions
Glaucoma, Open Angle or Ocular Hypertension
Interventions
brinzolamide 1% ophthalmic suspension, Azopt 1%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

NCT01312402
View directory record Official record
Conditions
Infantile Nystagmus Syndrome
Interventions
topical brinzolamide 1% in 5mL ophthalmic medication, Placebo in 5 mL dispenser
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

NCT01722604
View directory record Official record
Conditions
Glaucoma, Open Angle or Ocular Hypertension
Interventions
brinzolamide 1% ophthalmic suspension, Azopt 1%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00314158
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension, Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension, Timolol 5 mg/ml eye drops, solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

NCT00759941
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
35 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04024072
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

NCT02512042
View directory record Official record
Conditions
Glaucoma
Interventions
Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Newport Beach, California • Largo, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

NCT00800540
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 25, 2026, 4:58 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 25, 2026, 4:58 PM EDT